Value Investors: Buy Canada’s Best Pharmaceutical Stock

CRH Medical Corporation (TSX:CRH) could become a market leader in the gastrointestinal business. Investors could still purchase the stock, as higher acquisition offers than the one recently made are likely.

| More on:

CRH Medical (TSX:CRH) is a North American company focused on providing physicians throughout the United States with innovative products and services for the treatment of gastrointestinal (GI) diseases. The company distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves.

A few days back, WELL Health Technologies (TSX:WELL) recently announced a deal to acquire CRH for $369.2 million. This is expected to be a wonderful acquisition for WELL Health, which is raising equity from several high-profile investors, including Mr. Li Ka-shing, Hong Kong’s most famous business tycoon, to fund the purchase. WELL Health is expected to raise equity at a 25% premium to the volume weighted average price due to significant investor demand.

At the acquisition price, CRH is valued a price-to-earnings ratio of 97.60, price-to-book ratio of 4.83, and market capitalization of $349 million. Debt is very sparingly used at CRH, as evidenced by a debt-to-equity ratio of just 0.96. Prior to the takeover offer, CRH reported depressed performance metrics with an operating margin of (7.95)% and a return on equity of (2.6)%.

The CRH O’Regan System is a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. In 2014, CRH acquired Gastroenterology Anesthesia Associates (GAA), a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures. Performing these procedures under anesthetic provides more comfort for patients. CRH has continued to leverage the capabilities it acquired through GAA to consolidate the highly fragmented gastroenterology anesthesia provider business.

CRH’s goal is to establish itself as the premier provider of innovative products and essential services to gastroenterologists. The company has been on a shopping spree over the last five years, buying up anesthesia services providers in the United States. Most recently, CRH acquired 100% of certain assets of Anesthesia Care Associates, an anesthesia services provider in Indiana.

The company’s management, medical and support teams have developed specific skills and knowledge in the United States (U.S.) healthcare market. The extent and breadth of CRH’s experience delivering healthcare services, developed through years of operating across multiple U.S. states, have provided it with a national scope of knowledge that is not easily acquired or replicated.

CRH’s management has acquired the knowledge necessary to gather and process the critical information required to enter prospective markets. The company has developed this knowledge and expertise by acquiring new personnel with the requisite skill sets.

CRH outsources design and manufacturing activities to save on costs. However, the company maintains direct control over customer service activities to ensure that it provides the best service to customers. Through an established system of customer feedback, CRH monitors for signs of quality problems and customer issues. CRH has also established a feedback system to provide early warning of quality problems and to determine whether it has met the customer’s requirements.

In summary, CRH could become a market leader in the gastrointestinal business which could result in a significantly higher stock price. Investors could still purchase the stock, as higher acquisition offers than the one made by WELL Health are likely.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned. The Motley Fool owns shares of CRH Medical.

More on Investing

Printing canadian dollar bills on a print machine
Dividend Stocks

How to Turn a $14,000 TFSA Into a Cash Generating Machine

Two blue chip pipeline stocks quietly pay you to do nothing. Here is the simple math that TFSA investors should…

Read more »

chart reflected in eyeglass lenses
Top TSX Stocks

5 Cheap Canadian Stocks to Buy Before the Market Notices

Explore five cheap Canadian stocks that remain overlooked and may offer strong long‑term upside as fundamentals improve.

Read more »

young adult uses credit card to shop online
Tech Stocks

The Best TSX Stock to Buy Before it Recovers

This top TSX stock has dropped significantly but has multiple growth catalysts that could spur a swift recovery in its…

Read more »

golden sunset in crude oil refinery with pipeline system
Energy Stocks

Enbridge vs Suncor: The Dividend Pick I’d Own Through 2026

Enbridge stock currently has a strong dividend yield of almost 5%, with a business that's ready to meet the energy…

Read more »

Nuclear power station cooling tower
Dividend Stocks

1 Magnificent TSX Dividend Stock Down 20% to Buy and Hold For Decades

This infrastructure builder just posted record numbers, yet the market is treating it like an afterthought.

Read more »

dividends grow over time
Dividend Stocks

1 Dividend Stock That’s Been Quietly, But Constantly, Raising Its Dividend

Chemtrade’s monthly distribution has been climbing, and its cash-flow coverage suggests the payout isn’t just a headline.

Read more »

Piggy bank on a flying rocket
Bank Stocks

1 Reliable Dividend Stock Worth Buying Even If You Only Have $400 to Invest

CIBC (TSX:CM) shares are still cheap and could be a great buy to pull ahead of inflation.

Read more »

dividend growth for passive income
Dividend Stocks

5 TSX Dividend Stocks With Solid Yields Built for Steady Cash Flow in Any Market

These TSX dividend stocks are supported by fundamentally strong businesses, resilient earnings, and sustainable payouts.

Read more »